Benefit from Dose-Dense Chemotherapy for Breast Cancer
Author Information
Author(s): Matikas Alexios, Papakonstantinou Andri, Loibl Sibylle, Steger Günther G., Untch Michael, Johansson Hemming, Tsiknakis Nikos, Hellström Mats, Greil Richard, Möbus Volker, Gnant Michael, Bergh Jonas, Foukakis Theodoros
Primary Institution: Karolinska Institutet
Hypothesis
Can dose-dense chemotherapy provide significant benefits for patients with high-risk breast cancer compared to standard treatment?
Conclusion
Dose-dense chemotherapy improves outcomes for all patients with primary resected high-risk breast cancer without any subgroup identified that does not benefit.
Supporting Evidence
- Median follow-up was 10.3 years.
- Treatment with tDD EC/D improved 10-year BCRFS across all subgroups.
- Absolute benefit from tDD EC/D was stable across risk-defined subpopulations.
- PREDICT underestimated overall survival in the entire population and across all subgroups.
- No differential treatment effect over time was observed.
Takeaway
This study shows that giving chemotherapy more frequently helps breast cancer patients do better, and all patients should consider this treatment.
Methodology
The study was a phase 3 randomized trial comparing tailored dose-dense chemotherapy to standard interval chemotherapy in high-risk breast cancer patients.
Potential Biases
Potential biases due to the open-label nature of the study and the subjective nature of some endpoints.
Limitations
The study's open-label design may have influenced outcomes, and the treatment approach has evolved since the trial was conducted.
Participant Demographics
Women aged 18-65 years with high-risk non-metastatic breast cancer.
Statistical Information
P-Value
0.026
Confidence Interval
95% CI 0.30–0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website